A share price of ASLAN Pharmaceuticals Ltd ADR [ASLN] is currently trading at $0.70, up 47.40%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The ASLN shares have gain 48.94% over the last week, with a monthly amount glided 6.06%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 8, January 2024, ASLAN Pharmaceuticals Announces Receipt of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement. In a post published today on Yahoo Finance, ASLAN Pharmaceuticals (NASDAQ: ASLN) (“ASLAN” or the “Company”), announced today that on January 5, 2024, it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) indicating that the Company is not in compliance with the US$1.00 minimum bid price requirement under the Nasdaq Listing Rules (the “Listing Rules”). Based on the closing bid price of the Company’s listed securities for the 30 consecutive business days ended January 4, 2024, the Company has not met the minimum bid price requirement set forth in Listing Rule 5550(a)(2) during that period. The Notice is only a notification of deficiency and has no immediate effect on the listing of the Company’s American Depositary Shares (“ADS”). The Company’s ADSs will continue to trade on the Nasdaq Capital Market at this time. The Company’s receipt of the Notice does not impact the Company’s business, operations or reporting requirements with the Securities and Exchange Commission.
From an analyst’s perspective:
ASLAN Pharmaceuticals Ltd ADR [NASDAQ: ASLN] stock has seen the most recent analyst activity on July 09, 2021, when Jefferies initiated its Buy rating and assigned the stock a price target of $8. Previously, H.C. Wainwright reaffirmed its Buy rating on January 14, 2019, and dropped its price target to $8.50.
ASLAN Pharmaceuticals Ltd ADR experienced fluctuations in its stock price throughout the past year between $0.39 and $4.69. Currently, Wall Street analysts expect the stock to reach $5.5 within the next 12 months. ASLAN Pharmaceuticals Ltd ADR [NASDAQ: ASLN] shares were valued at $0.70 at the most recent close of the market. An investor can expect a potential return of 685.71% based on the average ASLN price forecast.
Analyzing the ASLN fundamentals
Gross Profit Margin for this corporation currently stands at 1.0% with Operating Profit Margin at -3.69%, Pretax Profit Margin comes in at -3.75%, and Net Profit Margin reading is -3.77%. To continue investigating profitability, this company’s Return on Assets is posted at -1.01, Equity is -7.61 and Total Capital is -1.87. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at -43.47.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.5501 points at the first support level, and at 0.4001 for the second support level. However, for the 1st resistance point, the stock is sitting at 0.7800, and for the 2nd resistance point, it is at 0.8599.
ASLAN Pharmaceuticals Ltd ADR [ASLN] reported earnings per share of -$0.56 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.78/share, meaning a difference of $0.22 and a surprise factor of 28.20%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.11 per share as compared to estimates of -$0.8 per share, a difference of $0.69 representing a surprise of 86.20%.
Ratios To Look Out For
To put it in perspective, the Current Ratio for ASLAN Pharmaceuticals Ltd ADR [NASDAQ:ASLN] is 2.11. Also, the Quick Ratio is 2.11, while the Cash Ratio stands at 1.95. Considering the valuation of this stock, the price to sales ratio is 0.98.
